

# Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor

N Smith, H Ismail, N Schellack

Department of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University  
Corresponding author, email: [natalie.schellack@smu.ac.za](mailto:natalie.schellack@smu.ac.za)

## Abstract

Neuropathic pain affects a large proportion of the population and reduces a person's ability to perform optimally. In South Africa, there are a host of factors that hinder the correct diagnosis and treatment of neuropathic pain. Patients suffering from neuropathic pain are treated suboptimally with NSAIDs and opioids as first-line therapy. In 2012, a South African guideline on neuropathic pain was released, which stated that opioid therapy should be reserved for last-line treatment only. More recently, melatonin, commonly known as the neurohormone that regulates the circadian rhythm, has come to light as a therapeutic treatment option in the neuropathic pain setting. Early clinical trials showed a link between melatonin and chronic pain, which includes neuropathic pain. The MT<sub>2</sub> receptor has also been specifically linked to the control of neuropathic pain and inflammation.

**Keywords:** melatonin, neuropathic pain, MT<sub>2</sub> receptor, opioids, NSAIDs

## Introduction

### What is neuropathic pain?

Neuropathic pain is considered to be a major health problem and affects a significant number of patients, thus leading to a rise in healthcare costs and reduced productivity.<sup>1</sup> Neuropathic pain can occur from injury to any point along a neuronal pathway, from the terminal of the peripheral nociceptors, to the cortical neurons in the brain.<sup>2</sup> In 2011 the International Association for the Study of Pain published the following definition of neuropathic pain: "pain caused by a lesion or disease of the somatosensory system".<sup>3</sup> The somatosensory system forms part of the sensory system and is associated with feelings like pain, touch, any movement, any change in temperature and position. The somatosensory system may respond to stimuli that originate from within the skin, muscles and joints.<sup>4</sup>

Due to the absence of effective treatment, there is a high prevalence of neuropathic pain. The use of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids is highly effective in the treatment of nociceptive pain, but only has a modest effect in a minority of patients that suffer from neuropathic pain. The main reason for this is because the underlying mechanism of neuropathic pain is not clearly understood.<sup>5</sup> Melatonin has demonstrated to possess a good safety and efficacy profile during the treatment of both nociceptive and neuropathic pain in several studies.<sup>6</sup>

### Local challenges

In South Africa there are a number of challenges which affect the diagnosis and treatment of neuropathic pain, including a lack of education amongst doctors about neuropathic pain. This, in turn,

leads to suboptimal diagnosis and treatment of neuropathic pain. Inappropriate use of opioids and NSAIDs as first-line therapy, as well as inappropriate back surgery is common. Therefore, many patients do not respond satisfactorily to current therapies.<sup>7</sup>

### Classification of neuropathic pain

Pain may be categorised into two main types, namely nociceptive pain and neuropathic pain. The distinction is important as it reflects the cause of pain and thus guides the treatment thereof.<sup>5</sup>

Neuropathic pain is further classified as being either central (originating from injury to the brain or spinal cord) or peripheral (originating from injury to the peripheral nerve, plexus, dorsal root ganglion, or root). Neuropathic pain is also classified on the basis of the aetiology of the insult to the nervous system.<sup>2</sup> In addition, it may be characterised by intermittent or continuous, spontaneous pain, by provoked pain, by paraesthesias, dysesthesias and other positive symptoms, and by negative symptoms that reflect neural damage.<sup>2</sup> Refer to Table I.

### Signs and symptoms of neuropathic pain

Neuropathic pain is known to be chronic and does not respond to drug treatment. Hyperalgesic (increased sensitivity to stimuli) and allodynic (pain due to a stimulus that does not normally activate the nociceptive system) are two symptoms commonly found in neuropathic pain.<sup>8</sup> Other common features associated with neuropathic pain include paraesthesia (abnormal sensations), dysesthesia (unpleasant sensations), hypoesthesia (decreased sensitivity to stimulation), hypoalgesia (diminished response to a normally painful stimulus) and hyperalgesia (exaggerated response to a normally painful stimulus).<sup>2,9</sup>

**Table 1:** Classification of neuropathic and nociceptive pain<sup>5</sup>

<b>Neuropathic pain</b>	<b>Nociceptive pain</b>
<b>Aetiology</b>	<b>Aetiology</b>
<ul style="list-style-type: none"> <li>• Injury to the nervous system, often accompanied by maladaptive changes in the nervous system</li> </ul>	<ul style="list-style-type: none"> <li>• Can cause damage to tissues</li> </ul>
<b>Description</b>	<b>Description</b>
<ul style="list-style-type: none"> <li>• Lancing, shooting, electric-like, stabbing pain</li> </ul>	<ul style="list-style-type: none"> <li>• Pressure-like pain that can be accompanied by throbbing and aching.</li> </ul>
<b>Sensory deficits</b>	<b>Sensory deficits</b>
<ul style="list-style-type: none"> <li>• Common symptoms like numbness, tingling, pricking</li> </ul>	<ul style="list-style-type: none"> <li>• Uncommon, if present they have a non-dermatomal or non-nerve distribution</li> </ul>
<b>Motor deficits</b>	<b>Motor deficits</b>
<ul style="list-style-type: none"> <li>• If a motor nerve is affected then neurological weakness may be present. Central and peripheral nervous system lesions will result in dystonia and spasticity</li> </ul>	<ul style="list-style-type: none"> <li>• Can cause pain-induced weakness</li> </ul>
<b>Hypersensitivity</b>	<b>Hypersensitivity</b>
<ul style="list-style-type: none"> <li>• Pain often caused by a usually non-painful stimulus (allodynia) or by an exaggerated response to a usually painful stimulus</li> </ul>	<ul style="list-style-type: none"> <li>• Hypersensitivity usually occurs in the immediate area surrounding an acute injury but is otherwise uncommon</li> </ul>
<b>Character</b>	<b>Character</b>
<ul style="list-style-type: none"> <li>• Distal radiation common</li> </ul>	<ul style="list-style-type: none"> <li>• Distal radiation less common; proximal radiation more common</li> </ul>
<b>Paroxysms</b>	<b>Paroxysms</b>
<ul style="list-style-type: none"> <li>• Exacerbations common and unpredictable</li> </ul>	<ul style="list-style-type: none"> <li>• Exacerbations less common and often associated with activity</li> </ul>
<b>Autonomic signs</b>	<b>Autonomic signs</b>
<ul style="list-style-type: none"> <li>• In almost half the patients sudomotor (sweating) occurs; this could be accompanied by a change in temperature, swelling and colour changes</li> </ul>	<ul style="list-style-type: none"> <li>• Uncommon</li> </ul>

**Diagnosis of neuropathic pain**

It is critical to appropriately investigate and characterise the underlying pathology of neuropathic pain and to intervene early. Neuropathic pain can be difficult to diagnose due to the fact that there are no standard diagnostic procedures to follow. A comprehensive evaluation will need to be done, which includes taking a thorough patient history and evaluating the patient’s neurological and physical symptoms. Clinicians may also diagnose neuropathic pain if a nerve lesion is found.<sup>9</sup> The patient’s sensory abilities (touch, temperature, vibrations and pinprick) should be assessed along with the patient’s mood (anxiety). The presence of a Babinsky reflex, accelerated tendon reflexes and spasticity should be determined.<sup>10</sup> Improved awareness about neuropathic pain amongst both healthcare professionals and patients will improve the ultimate management of neuropathic pain.<sup>2,11</sup> Refer to Figure 1.


**Pathway of melatonin in pain modulation**

The precise mechanism of pain modulation is not completely understood; however, evidence suggests that many systems, including the opioid system and nitric oxide pathways, play a role in melatonin pain modulation. Melatonin has a high degree of lipid solubility and a wide distribution of binding sites throughout the central nervous system (CNS). It is therefore able to cross the blood-brain barrier, which suggests central nociceptive regulation of melatonin.<sup>8</sup>

**The MT<sub>2</sub> receptor**

**What is the M<sub>2</sub> receptor?**

The MT<sub>1</sub> and MT<sub>2</sub> receptors are the two membrane-bound G-protein coupled receptors of melatonin. The MT<sub>3</sub> receptor has been found in other areas of the body including the kidney, liver and ovaries.<sup>12,13</sup>



**Figure 1:** Diagnosis of neuropathic pain<sup>9</sup>

A large number of experiments suggest that the MT<sub>1</sub> and MT<sub>2</sub> receptors play an important role in pain modulation. This is because these receptors influence a number of systems, including the opioid system, adrenergic system and secondary messenger system.<sup>8</sup> Zurowski et al<sup>14</sup> confirm that exogenous melatonin has antinociceptive effects and it influences the pain threshold via modulation of the opioid system. Melatonin also exerts its antinociceptive effects by activating the MT<sub>1</sub>/MT<sub>2</sub> receptor pathway and thus proves that a MT<sub>1</sub>/MT<sub>2</sub> receptor agonist could become a therapeutic option in the treatment of pain.<sup>14</sup>

### Localisation of the M<sub>2</sub> receptor

The MT<sub>2</sub> receptor has been implicated in non-rapid eye movement sleep (NREM) in humans and other mammals such as rats.<sup>12,13</sup>

Danilov and Kurganova<sup>6</sup> (2016) also confirm the localisation of the MT<sub>2</sub> receptors in various regions of the brain, such as the pars tuberalis of the pituitary gland, the hypothalamus, the cerebellum, the frontal cortex, the nucleus accumbens, the amygdala and the hippocampus, thus suggesting that the MT<sub>2</sub> receptor has a distinct function in the neurophysiological and neuropathological systems. The MT<sub>2</sub> receptor was also found to play a direct and indirect role in the secretion of vasopressin and oxytocin, supporting a role of melatonin in the control of uterine contractions, because of its localisation in the paraventricular nucleus and the magnocellular preoptic and supraoptic nuclei.<sup>6</sup>

Abnormal expression of the MT<sub>2</sub> receptor has been linked to neurodegenerative diseases. It has been documented that abnormal expression of the MT<sub>2</sub> receptors in the hippocampus and the cortex have been linked to Alzheimer's disease. Furthermore, post-mortem examinations have indicated that there is a decrease in the expression of MT<sub>2</sub> receptors in the substantia nigra in patients with Parkinson's disease.<sup>6,12</sup>

Furthermore, it has been suggested that the MT<sub>2</sub> receptor is involved in the motor effects of systemic administration of melatonin in the substantia nigra pars reticulata, red nucleus, the oculomotor, parabrachial nuclei and the colliculi.<sup>15</sup>

Recently the role of the MT<sub>2</sub> receptors and melatonin has been documented in the control of neuropathic pain and inflammation. Because of the MT<sub>2</sub> receptor localisation in the descending nociceptive pathways, the pharmacological and physiological properties of melatonin have been proved.<sup>6</sup>

### Management of neuropathic pain

In 2012, Chetty et al<sup>7</sup> published a guideline for the management of neuropathic pain in South Africa. After accurately diagnosing neuropathic pain, it is recommended that pregabalin, gabapentin, low-dose tricyclic antidepressants (e.g. amitriptyline) and dual serotonin-noradrenaline reuptake inhibitors (venlafaxine and duloxetine) be used as first-line treatment options in the management of neuropathic pain.

If there is no response, or the response is limited to the selected first-line treatment option after two to four weeks, it is recommended to switch to a different class or to combine classes of agents. Opioid therapy should be reserved for when combination therapy fails. For central neuropathic pain it is recommended that amitriptyline or pregabalin be used as first-line therapy.<sup>7</sup>

### Melatonin

Melatonin is known as an exceptional neurohormone, synthesised from serotonin and secreted by the pineal gland. Melatonin secretion follows a distinct circadian rhythm,<sup>8,12</sup> and the gland is located deep in the centre of the brain.<sup>16</sup> The route by which melatonin is supplied to the brain follows its direct release into the cerebrospinal fluid (CSF) of the third ventricle.<sup>17</sup>

Melatonin is known to be a versatile molecule and has a wide distribution throughout the body. Thus, the molecule plays a role in a number of physiological functions, which include sleep modulation, circadian rhythm, reproduction and vasomotor responses.<sup>6, 8, 13</sup>

According to Anwar et al,<sup>13</sup> melatonin has additional physiological effects, other than the regulation of the circadian rhythm. Melatonin is reported to act as a hypnotic, antiepileptic, immune modulator and antidepressant, and also plays a role in cardiovascular and bone disease.<sup>13</sup> Melatonin is also known as an antioxidant and anti-apoptotic agent, because of its ability to reduce the formation of reactive oxygen and nitrogen species.<sup>13</sup> During tissue damage and inflammation a variety of inflammatory mediators, including reactive oxygen species, are released. Evidence indicates that reactive oxygen species are involved in chronic pain, which includes neuropathic pain.<sup>18</sup> Clinical trials that were mainly conducted on chronic pain, such as migraines and fibromyalgia, have proven that melatonin eases pain, and improves sleep and depression.<sup>1, 6, 8</sup>

Early clinical trials suggested that there is a connection between the action of melatonin and nociceptive pain. Patients who suffered from chronic pain had significantly lowered levels of melatonin in their blood and urine. Patients with fibromyalgia also had lowered concentrations of the melatonin precursors, L-tryptophan and serotonin.<sup>14</sup>

The physiological effects of melatonin are manifested due to the activation of the MT<sub>1</sub> and MT<sub>2</sub> receptors that are located in the brain.<sup>1</sup>

Clinical trials have shown that melatonin has analgesic properties in chronic pain. A number of animal studies have demonstrated that melatonin has anti-inflammatory and antinociceptive effects in chronic neuropathic pain, which are mediated by the MT<sub>2</sub> receptor.<sup>1</sup> Experiments have supported the analgesic and antihyperalgesic effect of melatonin in neuropathic pain.<sup>8</sup> It has been discovered that the maximum analgesic effect of melatonin occurs at night due to its circadian rhythm concentration in the blood, and that surgically removing the pituitary gland will inhibit this effect.<sup>14</sup>

## Conclusion

The nature of neuropathic pain poses significant healthcare challenges, especially in terms of the effective alleviation of the symptoms thereof. This may be exacerbated by potential delays in correctly diagnosing patients suffering from this form of chronic pain. Recent advances include moving away from the more traditional pain management approach, of utilising staggered and combined treatment options belonging to the opioid and NSAID group of pharmacotherapeutic agents, to alternative treatment options that include pregabalin, gabapentin, low-dose tricyclic antidepressants and dual serotonin-noradrenaline reuptake inhibitors, as well as melatonin.

## References

- Lopez-Canul M, Palazzo E, Dominguez-Lopez S, et al. Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. *PAIN*. 2015;156(2):305–317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25599452> (Accessed 22 June 2016)
- Haanpää M, Treede R. 2010. Diagnosis and Classification of Neuropathic Pain. *International Association for the Study of Pain*. Volume XVIII. Issue 7.
- Jensen T, Baron R, Haanpää M, et al. A new definition of neuropathic pain. *Pain*. 2011;152(10):2204–2205. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21764514> (Accessed 22 June 2016)
- Somatosensory System Anatomy. *Medscape* 12 July 2013. Available at: <http://emedicine.medscape.com/article/1948621-overview> (Accessed 14 June 2016)
- Cohen S, Mao J. Neuropathic pain: mechanisms and their clinical implications. *BMJ*. 2014;348(feb05 6):f7656–f7656. Available at: doi: 10.1136/bmj.f7656 [Accessed 22 June 2016]
- Danilov A, Kurganova J. Melatonin in chronic pain syndromes. *Pain Ther*. 2016;5(1):1–17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26984272> (Accessed 27 June 2016)
- Chetty S, Baalbergen E, Bhigjee A, et al. Clinical practice guidelines for management of neuropathic pain: expert panel recommendations for South Africa. *South African Family Practice*. 2013;55(2):143–156. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22554341> (Accessed 28 June 2016)
- Liu Y, He H, Huang F. Melatonin in Pain Modulation: Analgesic or Proalgesic?. *PST*. 2014;02(02):50–55. Available at: <http://dx.doi.org/10.4236/pst.2014.22009> (Accessed 22 June 2016)
- Veterans' Medicines Advise and Therapeutics Education Services. Topic 35: Managing neuropathic pain: a stepwise approach. 2013. Available at: [https://www.apsoc.org.au/PDF/Publications/Veterans\\_MATES\\_35\\_Neuropathic\\_Pain\\_TherBrief\\_JUN13.pdf](https://www.apsoc.org.au/PDF/Publications/Veterans_MATES_35_Neuropathic_Pain_TherBrief_JUN13.pdf) (Accessed 22 June 2016)
- Scherder E, Plooij B. Assessment and management of pain, with particular emphasis on central neuropathic pain, in moderate to severe dementia. *Drugs Aging*. 2012;29(9):701–706. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23018606> (Accessed 28 June 2016)
- Treede R, Jensen T, Campbell J, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. *Neurology*. 2007;70(18):1630–1635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18003941> (Accessed 22 June 2016)
- Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. *Journal of Psychiatry and Neuroscience*. 2014;39(1):6–21. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23971978> (Accessed 22 June 2016)
- Anwar M, Muhammad B, Bader A, et al. An insight into the scientific background and future perspectives for the potential uses of melatonin. *Egyptian Journal of Basic and Applied Sciences*. 2015;2(3):139–152. Available at: <http://www.sciencedirect.com/science/article/pii/S2314808X15000354> (Accessed 22 June 2016)
- Zurowski D, Nowak L, Machowska A, et al. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. *J Physiol Pharmacol*. 2012;63(6):641–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23388480> (Accessed 23 June 2016)
- Lacoste B, Angeloni D, Dominguez-Lopez S, et al. Anatomical and cellular localization of melatonin MT 1 and MT 2 receptors in the adult rat brain. *J Pineal Res*. 2015;58(4):397–417. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25726952> (Accessed 22 June 2016)
- Sargis R. An overview of the pineal gland [Internet]. *EndocrineWeb*. 2016 (cited 22 June 2016). Available from: <http://www.endocrineweb.com/endocrinology/overview-pineal-gland>
- Reiter R, Tan D, Kim S, Cruz M. Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanyocytes and Virchow–Robin perivascular spaces. *Brain Structure and Function*. 2014;219(6):1873–1887. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24553808> (Accessed 22 June 2016)
- Srinivasan V, Zakaria R, Singh HJ, Acuña-Castroviejo D. Melatonin, its agonists in pain modulation: clinical application. *Archives Italiennes de Biologie*. 2012;150(4):274–289. Available at: [www.architalbiol.org/aib/article/download/150274/23479460](http://www.architalbiol.org/aib/article/download/150274/23479460) (Accessed 23 June 2016)